Enanta Pharmaceuticals (ENTA) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$416.9 million.
- Enanta Pharmaceuticals' Retained Earnings fell 2071.55% to -$416.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$416.9 million, marking a year-over-year decrease of 2071.55%. This contributed to the annual value of -$404.9 million for FY2025, which is 2534.95% down from last year.
- Per Enanta Pharmaceuticals' latest filing, its Retained Earnings stood at -$416.9 million for Q4 2025, which was down 2071.55% from -$404.9 million recorded in Q3 2025.
- Enanta Pharmaceuticals' 5-year Retained Earnings high stood at $97.2 million for Q1 2021, and its period low was -$416.9 million during Q4 2025.
- In the last 5 years, Enanta Pharmaceuticals' Retained Earnings had a median value of -$192.9 million in 2023 and averaged -$178.8 million.
- In the last 5 years, Enanta Pharmaceuticals' Retained Earnings plummeted by 82408.3% in 2023 and then plummeted by 2071.55% in 2025.
- Over the past 5 years, Enanta Pharmaceuticals' Retained Earnings (Quarter) stood at $18.5 million in 2021, then crashed by 653.41% to -$102.2 million in 2022, then plummeted by 135.31% to -$240.4 million in 2023, then crashed by 43.65% to -$345.3 million in 2024, then fell by 20.72% to -$416.9 million in 2025.
- Its Retained Earnings was -$416.9 million in Q4 2025, compared to -$404.9 million in Q3 2025 and -$386.2 million in Q2 2025.